Immunological recovery and antiretroviral therapy in HIV-1 infection

M Battegay, R Nüesch, B Hirschel… - The Lancet infectious …, 2006 - thelancet.com
Potent antiretroviral therapy has dramatically improved the prognosis of patients infected
with HIV-1. Primary and secondary prophylaxis against Pneumocystis carinii …

Where does HIV live?

J Stebbing, B Gazzard, DC Douek - New England Journal of …, 2004 - Mass Medical Soc
This survey of the cellular and anatomical sites of infection by human immunodeficiency
virus (HIV) discusses the mechanisms of attachment of the virus to cells, the cellular …

The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies

G Namazi, JM Fajnzylber, E Aga… - The Journal of …, 2018 - academic.oup.com
Background HIV posttreatment controllers are rare individuals who start antiretroviral
therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of …

Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

J Niessl, AE Baxter, P Mendoza, M Jankovic… - Nature medicine, 2020 - nature.com
Combination antiretroviral therapy (ART) is highly effective in controlling human
immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a …

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

A Trkola, H Kuster, P Rusert, B Joos, M Fischer… - Nature medicine, 2005 - nature.com
To determine the protective potential of the humoral immune response against HIV-1 in vivo
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …

HIV rebounds from latently infected cells, rather than from continuing low-level replication

B Joos, M Fischer, H Kuster, SK Pillai… - Proceedings of the …, 2008 - National Acad Sciences
Rapid rebound of plasma viremia in patients after interruption of long-term combination
antiretroviral therapy (cART) suggests persistence of low-level replicating cells or rapid …

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial

J Ananworanich, A Gayet-Ageron, M Le Braz… - The Lancet, 2006 - thelancet.com
Background Stop** antiretroviral therapy in patients with HIV-1 infection can reduce costs
and side-effects, but carries the risk of increased immune suppression and emergence of …

CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial

C Danel, R Moh, A Minga, A Anzian, O Ba-Gomis… - The Lancet, 2006 - thelancet.com
Background Structured treatment interruptions of highly-active antiretroviral therapy
(HAART) might be particularly relevant for sub-Saharan Africa, where cost-saving strategies …

[HTML][HTML] Next-generation bNAbs for HIV-1 cure strategies

AI Schriek, YLT Aldon, MJ van Gils, SW de Taeye - Antiviral research, 2024 - Elsevier
Despite the ability to suppress viral replication using anti-retroviral therapy (ART), HIV-1
remains a global public health problem. Curative strategies for HIV-1 have to target and …

Limited durability of viral control following treated acute HIV infection

DE Kaufmann, M Lichterfeld, M Altfeld, MM Addo… - PLoS …, 2004 - journals.plos.org
Background Early treatment of acute HIV infection with highly active antiretroviral therapy,
followed by supervised treatment interruption (STI), has been associated with at least …